Human monoclonal antibodies against SARS-CoV-2

NIH Pandemic-Era Grants

Pandemic Era Grants

2024

↗ Live URL (may be dead)

Document text

Principal Investigator: Joshua  Tan
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2024
Award: $339,952
Funding agency: National Institute of Allergy and Infectious Diseases

The overarching goal of this project is to study the immune response to COVID-19 at the monoclonal level to increase our understanding of basic biology and develop new tools to combat disease. We have screened plasma from >100 acutely infected and convalescent COVID-19 individuals for neutralization of authentic SARS-CoV-2. The top neutralizers were selected for antibody isolation and we have isolated a panel of monoclonals against the SARS-CoV-2 spike protein. 

In FY24, we followed up on prior work identifying broadly neutralizing antibodies against coronaviruses that target the spike fusion peptide and stem helix. We are now trying to identify next-generation antibodies that are more potent than the initially discovered antibodies, modifying existing antibodies to improve potency against coronaviruses, as well as designing vaccine constructs based on the antibodies that we identified.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><Active Follow-up><Acute><Antibodies><Biology><Blood Plasma><COVID-19><COVID-19 S protein><COVID-19 antibody><COVID-19 prevention><COVID-19 spike><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19 virus><CV-19><CoV emergence><CoV-2><CoV2><Coronaviridae><Coronavirus><Coronavirus Infectious Disease 2019><Disease><Disorder><Goals><Hu-mABs><Immune response><Immunological response><Individual><Peptides><Plasma><Plasma Serum><Resolution><Reticuloendothelial System, Serum, Plasma><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 S><SARS-CoV-2 S protein><SARS-CoV-2 antibody><SARS-CoV-2 spike><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome related corona virus 2><Technology><Testing><Vaccine Design><Virus><Work><Wuhan coronavirus><active followup><antibody against COVID-19><antibody against SARS-CoV-2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody to COVID-19><antibody to SARS-CoV-2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><beta CoV><beta coronavirus><betaCoV><betacoronavirus><combat><corona virus><corona virus emergence><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 antibody><coronavirus disease 2019 prevention><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 prevention><coronavirus disease-19 virus><coronavirus emergence><coronavirus infectious disease-19><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><follow up><follow-up><followed up><followup><global health><hCoV19><host response><humAbs><human mAbs><human monoclonal antibodies><human monoclonals><immune system response><immunoresponse><improved><interest><nCoV><nCoV2><neutralizing antibody><new CoV><new corona virus><new coronavirus><next generation><novel><novel CoV><novel corona virus><novel coronavirus><prevent COVID-19><prevent coronavirus disease 2019><resolutions><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><spike proteins on SARS-CoV-2><stem><tool><variants of concern><β CoV><β coronavirus><βCoV>